The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

CRISPR moves from the lab to human trials, targeting blindness, beta thalassemia and sickle cell anemia

| | August 19, 2019

It’s only been seven years since scientists first learned how to precisely and reliably splice the human genome using a tool called CRISPR, making it possible to think about snipping out disease-causing mutations and actually cure, once and for all, genetic diseases ranging from sickle cell anemia to certain types of cancer and even blindness.

Editas Medicine and Allergan recently announced a more acceptable form of gene editing… . They are enrolling patients born with a congenital vision disease into what will be the first test in the U.S. of whether CRISPR can fix a mutation in the cells of a living human body. Other ongoing trials, including one from partners Vertex Pharmaceuticals and CRISPR Therapeutics that is treating blood diseases, rely on treating patients’ cells outside of their body and introducing them back to the body… .

Related article:  Talking Biotech: TALEN gene editing to make more nutritious food crops

Scientists agree that CRISPR holds great promise in giving researchers unprecedented power to snip out abnormal stretches of DNA. … CRISPR works well enough in the lab, in a dish of human cells, but as with any technology, there are glitches. … Then there is the bigger question of what longer term, unanticipated effects man-made edits to the human genome might have.

Read full, original post: CRISPR Gene Editing Is Being Tested in Human Patients, and the Results Could Revolutionize Health Care

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend